CD19 and congenital rubella syndrome: While dex is a potent immunosuppressive agent,2,3 prophylactic corticosteroid use in patients receiving CD19-CAR T cells for toxicity management results in low rates of CRS, delayed CRS onset, and similar rates of neuro-toxicity, without adversely affecting CAR T cell pharmacokinetics or efficacy outcomes.5